Skip to content
Peptigraph home

AMAZE 2: Amycretin Phase 3 trial (NCT07533175)

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)

Registry record checked

At a glance

Phase
Phase 3
Status
Recruiting
Enrolment
630
estimated
Start
13 Apr 2026 (actual)
Primary completion
7 Aug 2028 (estimated)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT07533175 study arms
ArmTypeInterventionsDescription
NNC0487-0111 dose level 1ExperimentalDrug: NNC0487-0111Participants will be randomized to receive NNC0487-0111 dose level 1 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
NNC0487-0111 dose level 2ExperimentalDrug: NNC0487-0111Participants will be randomized to receive NNC0487-0111 dose level 2 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
NNC0487-0111 dose level 3ExperimentalDrug: NNC0487-0111Participants will be randomized to receive NNC0487-0111 dose level 3 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
NNC0487-0111 dose level 4ExperimentalDrug: NNC0487-0111Participants will be randomized to receive NNC0487-0111 dose level 4 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
PlaceboPlacebo comparatorDrug: Placebo (matched to NNC0487-0111)Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Endpoints

Primary endpoint

NCT07533175 primary outcomes
MeasureTime frame
Relative change in body weightFrom baseline (week 0) to (week 84)
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT07533175 secondary outcomes
MeasureTime frame
Change in waist circumferenceFrom baseline (week 0) to (week 84)
Change in glycated haemoglobin (HbA1c)From baseline (week 0) to (week 84)
Change in systolic blood pressure (SBP)From baseline (week 0) to (week 84)
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) physical function scoreFrom baseline (week 0) to (week 84)
Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning scoreFrom baseline (week 0) to (week 84)
Change in body weightFrom baseline (week 0) to (week 84)
Change in body mass index (BMI)From baseline (week 0) to (week 84)
Change in IWQOL-Lite-CT: Physical, Psychosocial, Total scoreFrom baseline (week 0) to (week 84)
Achievement of HbA1c < 7.0% (Yes/No)From baseline (week 0) to (week 84)
Achievement of HbA1c ≤ 6.5% (Yes/No)From baseline (week 0) to (week 84)
Achievement of HbA1c < 5.7% (Yes/No)From baseline (week 0) to (week 84)
Change in fasting plasma glucose (FPG) (mmol/L)From baseline (week 0) to (week 84)
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.